NCT00140504已完成不适用
Preventing Adverse Drug Events With PatientSite
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 800
- 试验地点
- 2
- 主要终点
- To prevent adverse drug events with PatientSite.
研究概览
简要总结
This is a study to better understand the nature and extent of adverse drug events (ADEs), defined as injuries due to prescription medications, in primary care. We will study whether PatientSite (an internet-based communication program for patients and health care providers) can improve clinicians' ability to detect adverse drug events among primary care patients and to mitigate the consequences by sending electronic queries to patients after they receive new medication prescriptions.
详细描述
- A drug safety module called MedCheck was developed for PatientSite. This allows physicians to query patients automatically 10 days after they receive a new prescription asking them questions about their new prescription. In this study new enhancements will be tested.
- Participants will be assigned at random to the intervention group or control group. The intervention group will receive a single electronic PatientSite message asking them questions about the new prescription which is then forwarded to their physician. The control group will receive a generic message about medication safety.
- To identify adverse drug events, a telephone survey and medical record review will be conducted of patients in the intervention group and controls.
- This study will run for 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult patients >18
- •Patients that receive a new prescription
- •Proficient in spoken and written english
排除标准
- 未提供
结局指标
主要结局
To prevent adverse drug events with PatientSite.
时间窗: 3 years
次要结局
- Improve patient satisfaction(3 years)
- better utilization of services(3 years)
- improve patient-clinician communication(3 years)
研究者
Saul N. Weingart, MD, PhD
VP for Quality Improvement and Patient Safety
Dana-Farber Cancer Institute
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral AnticoagulantsEmbolism and ThrombosisHemorrhageNCT02720328Cliniques universitaires Saint-Luc- Université Catholique de Louvain102
撤回
不适用
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement SurgeryThrombosis, Deep VeinPulmonary EmbolismCerebral StrokeNCT03804125Pfizer
已完成
不适用
Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With PainPainNCT02651363Bristol-Myers Squibb374
Unknown
不适用
Therapeutic Drug Monitoring for Individualized Clozapine TherapySchizophreniaNCT03523741Seoul National University Hospital100
已完成
3 期
Randomized Controlled Trial of Enhanced Pharmacy Care in Older Veteran OutpatientsGeriatricsDrug TherapyPoly PharmacyNCT00122122US Department of Veterans Affairs600
